{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:22:22Z","timestamp":1790702542038,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s11883-020-00867-3","type":"journal-article","created":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T01:02:18Z","timestamp":1595638938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis"],"prefix":"10.1007","volume":"22","author":[{"given":"Patrick M.","family":"Moriarty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauryn K.","family":"Gorby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S.","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,25]]},"reference":[{"key":"867_CR1","doi-asserted-by":"publisher","first-page":"m1091","DOI":"10.1136\/bmj.m1091","volume":"368","author":"T Chen","year":"2020","unstructured":"Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091. https:\/\/doi.org\/10.1136\/bmj.m1091.","journal-title":"BMJ."},{"issue":"1","key":"867_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12931-017-0553-6","volume":"18","author":"G Voiriot","year":"2017","unstructured":"Voiriot G, Razazi K, Amsellem V, Tran Van Nhieu J, Abid S, Adnot S, et al. Interleukin-6 displays lung anti-inflammatory properties and exerts protective hemodynamic effects in a double-hit murine acute lung injury. Respir Res. 2017;18(1):64. https:\/\/doi.org\/10.1186\/s12931-017-0553-6.","journal-title":"Respir Res"},{"key":"867_CR3","doi-asserted-by":"publisher","unstructured":"Gong J, Dong H, Xia SQ, Huang YZ, Wang D, Zhao Y et al. Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19 pneumonia. medRxiv. 2020:2020.02.25.20025643. https:\/\/doi.org\/10.1101\/2020.02.25.20025643.","DOI":"10.1101\/2020.02.25.20025643"},{"issue":"10","key":"867_CR4","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1161\/CIRCRESAHA.120.317055","volume":"126","author":"A Akhmerov","year":"2020","unstructured":"Akhmerov A, Marb\u00e1n E. COVID-19 and the heart. Circ Res. 2020;126(10):1443\u201355.","journal-title":"Circ Res"},{"key":"867_CR5","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1161\/circulationaha.120.046941","volume":"141","author":"KJ Clerkin","year":"2020","unstructured":"Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation. 2020;141:1648\u201355. https:\/\/doi.org\/10.1161\/circulationaha.120.046941.","journal-title":"Circulation."},{"key":"867_CR6","doi-asserted-by":"publisher","unstructured":"Klok FA, Kruip M, Van der Meer N, Arbous M, Gommers D, Kant K, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020:191;145\u2013147. https:\/\/doi.org\/10.1016\/j.thromres.2020.04.013. Demonstrates inflammatory markers such as IL-6 trend with troponin levels as a consequence of cytokine storm and myocardial injury association with COVID-19.","DOI":"10.1016\/j.thromres.2020.04.013"},{"key":"867_CR7","doi-asserted-by":"publisher","unstructured":"\u2022 Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med. 2020:e60. https:\/\/doi.org\/10.1056\/NEJMc2009787Single-site analysis showing evidence for higher risk for large vessel stroke in young individuals with mild COVID-19 symptoms.","DOI":"10.1056\/NEJMc2009787"},{"key":"867_CR8","doi-asserted-by":"publisher","unstructured":"Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, M\u00fcller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. n\/a(n\/a). https:\/\/doi.org\/10.1111\/jth.14888.","DOI":"10.1111\/jth.14888"},{"key":"867_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","volume":"191","author":"FA Klok","year":"2020","unstructured":"Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145\u20137. https:\/\/doi.org\/10.1016\/j.thromres.2020.04.013.","journal-title":"Thromb Res"},{"key":"867_CR10","doi-asserted-by":"publisher","unstructured":"Harzallah I, Debliquis A, Dr\u00e9nou B. Lupus anticoagulant is frequent in patients with Covid-19. J Thromb Haemost. n\/a(n\/a). https:\/\/doi.org\/10.1111\/jth.14867.","DOI":"10.1111\/jth.14867"},{"issue":"3","key":"867_CR11","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1172\/JCI118854","volume":"98","author":"S H\u00f6rkk\u00f6","year":"1996","unstructured":"H\u00f6rkk\u00f6 S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest. 1996;98(3):815\u201325.","journal-title":"J Clin Invest"},{"issue":"10","key":"867_CR12","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1194\/jlr.M040733","volume":"54","author":"G Leibundgut","year":"2013","unstructured":"Leibundgut G, Scipione C, Yin H, Schneider M, Boffa MB, Green S, et al. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res. 2013;54(10):2815\u201330. https:\/\/doi.org\/10.1194\/jlr.M040733.","journal-title":"J Lipid Res"},{"issue":"17","key":"867_CR13","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1056\/NEJMc2007575","volume":"382","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382(17):e38. https:\/\/doi.org\/10.1056\/NEJMc2007575COVID-19-infected patients presenting with thrombocytopenia, coagulopathy, and the presence of anticardiolipin antibodies had developed cerebral infarcts.","journal-title":"N Engl J Med"},{"issue":"4","key":"867_CR14","doi-asserted-by":"publisher","first-page":"e006631","DOI":"10.1161\/CIRCOUTCOMES.120.006631","volume":"13","author":"C-CF Tam","year":"2020","unstructured":"Tam C-CF, Cheung K-S, Lam S, Wong A, Yung A, Sze M, et al. Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment\u2013elevation myocardial infarction care in Hong Kong, China. Circ Cardiovasc Qual Outcomes. 2020;13(4):e006631.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"867_CR15","doi-asserted-by":"publisher","first-page":"e200067","DOI":"10.1148\/ryct.2020200067","volume":"2","author":"Y Xie","year":"2020","unstructured":"Xie Y, Wang X, Yang P, Zhang S. COVID-19 complicated by acute pulmonary embolism. Radiol Cardiothorac Imaging. 2020;2(2):e200067.","journal-title":"Radiol Cardiothorac Imaging"},{"key":"867_CR16","doi-asserted-by":"publisher","unstructured":"Marone EM, Rinaldi LF. Upsurge of deep venous thrombosis in patients affected by COVID-19: Preliminary data and possible explanations. J Vasc Surg Venous Lymphat Disord. (2020);8(4):694\u2013695. https:\/\/doi.org\/10.1016\/j.jvsv.2020.04.004.","DOI":"10.1016\/j.jvsv.2020.04.004"},{"issue":"2","key":"867_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ihj.2019.03.004","volume":"71","author":"EA Enas","year":"2019","unstructured":"Enas EA, Varkey B, Dharmarajan TS, Pare G, Bahl VK. Lipoprotein(a): an independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction. Indian Heart J. 2019;71(2):99\u2013112. https:\/\/doi.org\/10.1016\/j.ihj.2019.03.004.","journal-title":"Indian Heart J"},{"issue":"1","key":"867_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.17305\/bjbms.2010.2728","volume":"10","author":"V Topciu Shufta","year":"2010","unstructured":"Topciu Shufta V, Begolli L, Kryeziu E. Lipoprotein (a) as an acute phase reactant in patients on chronic hemodialysis. Bosn J Basic Med Sci. 2010;10(1):19\u201325. https:\/\/doi.org\/10.17305\/bjbms.2010.2728.","journal-title":"Bosn J Basic Med Sci"},{"issue":"6","key":"867_CR19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692\u2013711. https:\/\/doi.org\/10.1016\/j.jacc.2016.11.042.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"867_CR20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehz776","volume":"41","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Gordts PL, Nora C, Yeang C, Witztum JL. Statins and increases in Lp (a): an inconvenient truth that needs attention. Eur Heart J. 2020;41(1):192\u20133.","journal-title":"Eur Heart J"},{"key":"867_CR21","doi-asserted-by":"publisher","unstructured":"Tsimikas S, Gordts PL, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein (a) levels. Eur Heart J. 2019:41(24);2275\u20132284. https:\/\/doi.org\/10.1093\/eurheartj\/ehz310.","DOI":"10.1093\/eurheartj\/ehz310"},{"issue":"2\u20133","key":"867_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0021-9150(89)90218-9","volume":"78","author":"S Maeda","year":"1989","unstructured":"Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis. 1989;78(2\u20133):145\u201350. https:\/\/doi.org\/10.1016\/0021-9150(89)90218-9.","journal-title":"Atherosclerosis."},{"issue":"3","key":"867_CR23","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/s0735-1097(02)02769-9","volume":"41","author":"S Tsimikas","year":"2003","unstructured":"Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol. 2003;41(3):360\u201370. https:\/\/doi.org\/10.1016\/s0735-1097(02)02769-9.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"867_CR24","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1161\/01.CIR.0000141728.23033.B5","volume":"110","author":"S Tsimikas","year":"2004","unstructured":"Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 2004;110(11):1406\u201312. https:\/\/doi.org\/10.1161\/01.CIR.0000141728.23033.B5.","journal-title":"Circulation."},{"issue":"25","key":"867_CR25","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1161\/01.CIR.0000130844.01174.55","volume":"109","author":"S Tsimikas","year":"2004","unstructured":"Tsimikas S, Lau HK, Han KR, Shortal B, Miller ER, Segev A, et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation. 2004;109(25):3164\u201370. https:\/\/doi.org\/10.1161\/01.CIR.0000130844.01174.55.","journal-title":"Circulation."},{"key":"867_CR26","doi-asserted-by":"publisher","unstructured":"Nakamura A, Kanazawa M, Kagaya Y, Kondo M, Sato K, Endo H, et al. Plasma kinetics of mature PCSK9, furin-cleaved PCSK9, and Lp (a) with or without administration of PCSK9 inhibitors in acute myocardial infarction. J Cardiol. 2020. https:\/\/doi.org\/10.1016\/j.jjcc.2020.04.006.","DOI":"10.1016\/j.jjcc.2020.04.006"},{"issue":"4","key":"867_CR27","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood.V97.4.981","volume":"97","author":"C Buechler","year":"2001","unstructured":"Buechler C, Ullrich H, Ritter M, Porsch-Oezcueruemez M, Lackner KJ, Barlage S, et al. Lipoprotein (a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes. Blood. 2001;97(4):981\u20136.","journal-title":"Blood"},{"issue":"10","key":"867_CR28","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood.V98.10.2980","volume":"98","author":"NM Caplice","year":"2001","unstructured":"Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM, et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood. 2001;98(10):2980\u20137.","journal-title":"Blood"},{"issue":"10","key":"867_CR29","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1182\/blood.V96.10.3364","volume":"96","author":"M von Depka","year":"2000","unstructured":"von Depka M, Nowak-G\u00f6ttl U, Eisert R, Dieterich C, Barthels M, Scharrer I, et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood. 2000;96(10):3364\u20138.","journal-title":"Blood"},{"issue":"2","key":"867_CR30","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2015.08.021","volume":"242","author":"AH Nave","year":"2015","unstructured":"Nave AH, Lange KS, Leonards CO, Siegerink B, Doehner W, Landmesser U, et al. Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis. 2015;242(2):496\u2013503.","journal-title":"Atherosclerosis."},{"issue":"22","key":"867_CR31","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1161\/CIRCULATIONAHA.120.045826","volume":"141","author":"SC Larsson","year":"2020","unstructured":"Larsson SC, Gill D, Mason AM, Jiang T, B\u00e4ck M, Butterworth AS, et al. Lipoprotein (a) in Alzheimer, atherosclerotic, cerebrovascular, thrombotic, and valvular disease: Mendelian randomization investigation. Circulation. 2020;141(22):1826\u20138.","journal-title":"Circulation."},{"issue":"5 Suppl","key":"867_CR32","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.jacl.2015.07.006","volume":"9","author":"CJ McNeal","year":"2015","unstructured":"McNeal CJ. Lipoprotein(a): its relevance to the pediatric population. J Clin Lipidol. 2015;9(5 Suppl):S57\u201366. https:\/\/doi.org\/10.1016\/j.jacl.2015.07.006.","journal-title":"J Clin Lipidol"},{"issue":"8","key":"867_CR33","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jacc.2012.01.078","volume":"60","author":"A Helgadottir","year":"2012","unstructured":"Helgadottir A, Gretarsdottir S, Thorleifsson G, Holm H, Patel RS, Gudnason T, et al. Apolipoprotein (a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol. 2012;60(8):722\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"867_CR34","doi-asserted-by":"publisher","unstructured":"Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Cent Sci. (2020);6(5):672\u2013683. https:\/\/doi.org\/10.1021\/acscentsci.0c00489.","DOI":"10.1021\/acscentsci.0c00489"},{"key":"867_CR35","doi-asserted-by":"publisher","first-page":"108408","DOI":"10.1016\/j.clim.2020.108408","volume":"214","author":"J Ma","year":"2020","unstructured":"Ma J, Xia P, Zhou Y, Liu Z, Zhou X, Wang J, et al. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19. Clin Immunol. 2020;214:108408. https:\/\/doi.org\/10.1016\/j.clim.2020.108408A study demonstrating that the apheresis reduction of plasma cytokines may potentially improve late complications of critically ill COVID-19 patients.","journal-title":"Clin Immunol"},{"issue":"1","key":"867_CR36","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12967-020-02339-3","volume":"18","author":"B Fu","year":"2020","unstructured":"Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020;18(1):164. https:\/\/doi.org\/10.1186\/s12967-020-02339-3An interesting review outlining that the mechanism and function of a monoclonal antibody antagonist to IL-6 receptor may be effective in the treatment of COVID-19.","journal-title":"J Transl Med"},{"key":"867_CR37","unstructured":"Administration USFaD. Coronavirus (COVID-19) update: FDA authorizes blood purification device to treat COVID-19. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-blood-purification-device-treat-covid-192020. Accessed 10 Apr 2020."},{"issue":"6","key":"867_CR38","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1002\/j.1460-2075.1990.tb08316.x","volume":"9","author":"S Akira","year":"1990","unstructured":"Akira S, Isshiki H, Sugita T, Tanabe O, Kinoshita S, Nishio Y, et al. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C\/EBP family. EMBO J. 1990;9(6):1897\u2013906.","journal-title":"EMBO J"},{"issue":"4","key":"867_CR39","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1073\/pnas.90.4.1369","volume":"90","author":"DP Wade","year":"1993","unstructured":"Wade DP, Clarke JG, Lindahl GE, Liu AC, Zysow BR, Meer K, et al. 5\u2032 control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family. PNAS. 1993;90(4):1369\u201373.","journal-title":"PNAS."},{"issue":"5","key":"867_CR40","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1194\/jlr.P052209","volume":"56","author":"N Muller","year":"2015","unstructured":"Muller N, Schulte DM, Turk K, Freitag-Wolf S, Hampe J, Zeuner R, et al. IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J Lipid Res. 2015;56(5):1034\u201342. https:\/\/doi.org\/10.1194\/jlr.P052209.","journal-title":"J Lipid Res"},{"issue":"2","key":"867_CR41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.cell.2008.02.043","volume":"133","author":"Y Imai","year":"2008","unstructured":"Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, van Loo G, et al. Identification of oxidative stress and toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008;133(2):235\u201349.","journal-title":"Cell."},{"issue":"21","key":"867_CR42","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/j.jacc.2012.08.979","volume":"60","author":"S Tsimikas","year":"2012","unstructured":"Tsimikas S, Willeit P, Willeit J, Santer P, Mayr M, Xu Q, et al. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol. 2012;60(21):2218\u201329. https:\/\/doi.org\/10.1016\/j.jacc.2012.08.979.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"867_CR43","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","volume":"134","author":"FM van der Valk","year":"2016","unstructured":"van der Valk FM, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul JD, et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016;134(8):611\u201324. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.020838.","journal-title":"Circulation."},{"issue":"1","key":"867_CR44","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cmet.2019.10.014","volume":"31","author":"X Sun","year":"2020","unstructured":"Sun X, Seidman JS, Zhao P, Troutman TD, Spann NJ, Que X, et al. Neutralization of oxidized phospholipids ameliorates non-alcoholic steatohepatitis. Cell Metab. 2020;31(1):189\u2013206 e8. https:\/\/doi.org\/10.1016\/j.cmet.2019.10.014.","journal-title":"Cell Metab"},{"key":"867_CR45","doi-asserted-by":"publisher","unstructured":"Stiekema LCA, Prange KHM, Hoogeveen RM, Verweij SL, Kroon J, Schnitzler JG, et al. Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). Eur Heart J. 2020;41(24):2262\u20132271. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa171. The antisense apolipoprotein(a) therapy reduces proinflammatory activation of circulating monocytes in addition to lipoprotein(a).","DOI":"10.1093\/eurheartj\/ehaa171"},{"issue":"10","key":"867_CR46","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1161\/CIRCRESAHA.119.316206","volume":"126","author":"JG Schnitzler","year":"2020","unstructured":"Schnitzler JG, Hoogeveen RM, Ali L, KHM P, Waissi F, van Weeghel M, et al. Atherogenic lipoprotein(a) increases vascular glycolysis, thereby facilitating inflammation and leukocyte extravasation. Circ Res. 2020;126(10):1346\u201359. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.316206Lipoprotein(a) appears to activate inflammation and extravasation through a process of vascular glycolysis.","journal-title":"Circ Res"},{"issue":"7709","key":"867_CR47","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41586-018-0198-8","volume":"558","author":"X Que","year":"2018","unstructured":"Que X, Hung MY, Yeang C, Gonen A, Prohaska TA, Sun X, et al. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature. 2018;558(7709):301\u20136. https:\/\/doi.org\/10.1038\/s41586-018-0198-8.","journal-title":"Nature."},{"key":"867_CR48","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/0009-3084(94)90164-3","volume":"67\u201368","author":"A Noma","year":"1994","unstructured":"Noma A, Abe A, Maeda S, Seishima M, Makino K, Yano Y, et al. Lp(a): an acute-phase reactant? Chem Phys Lipids. 1994;67\u201368:411\u20137.","journal-title":"Chem Phys Lipids"},{"issue":"6","key":"867_CR49","first-page":"811","volume":"43","author":"I Kaklikkaya","year":"2002","unstructured":"Kaklikkaya I, Ozdemir R, Orem A, Unal M, Sonmez B, Ozcan F. Course of serum lipoprotein(a) and acute phase protein levels in patients undergoing open heart surgery. J Cardiovasc Surg (Torino). 2002;43(6):811\u20135.","journal-title":"J Cardiovasc Surg (Torino)"},{"issue":"12","key":"867_CR50","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1097\/00042737-200112000-00004","volume":"13","author":"IE Koutroubakis","year":"2001","unstructured":"Koutroubakis IE, Malliaraki N, Vardas E, Ganotakis E, Margioris AN, Manousos ON, et al. Increased levels of lipoprotein (a) in Crohn\u2019s disease: a relation to thrombosis? Eur J Gastroenterol Hepatol. 2001;13(12):1415\u20139. https:\/\/doi.org\/10.1097\/00042737-200112000-00004.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1\u20132","key":"867_CR51","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0009-8981(93)90063-A","volume":"223","author":"TB Ledue","year":"1993","unstructured":"Ledue TB, Neveux LM, Palomaki GE, Ritchie RF, Craig WY. The relationship between serum levels of lipoprotein(a) and proteins associated with the acute phase response. Clin Chim Acta. 1993;223(1\u20132):73\u201382.","journal-title":"Clin Chim Acta"},{"issue":"3","key":"867_CR52","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/1529-0131(199904)42:3<443::AID-ANR8>3.0.CO;2-Q","volume":"42","author":"Y Asanuma","year":"1999","unstructured":"Asanuma Y, Kawai S, Aoshima H, Kaburaki J, Mizushima Y. Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis. Arthritis Rheum. 1999;42(3):443\u20137. https:\/\/doi.org\/10.1002\/1529-0131(199904)42:3<443::AID-ANR8>3.0.CO;2-Q.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"867_CR53","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.atherosclerosis.2010.06.006","volume":"212","author":"F Apostolou","year":"2010","unstructured":"Apostolou F, Gazi IF, Lagos K, Tellis CC, Tselepis AD, Liberopoulos EN, et al. Acute infection with Epstein-Barr virus is associated with atherogenic lipid changes. Atherosclerosis. 2010;212(2):607\u201313. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2010.06.006.","journal-title":"Atherosclerosis."},{"issue":"6","key":"867_CR54","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1006\/cyto.2002.1044","volume":"18","author":"L Horvath","year":"2002","unstructured":"Horvath L, Csaszar A, Falus A, Dieplinger H, Horvath A, Puskas E, et al. IL-6 and lipoprotein(a) [LP(a)] concentrations are related only in patients with high APO(a) isoforms in monoclonal gammopathy. Cytokine. 2002;18(6):340\u20133. https:\/\/doi.org\/10.1006\/cyto.2002.1044.","journal-title":"Cytokine."},{"issue":"12","key":"867_CR55","doi-asserted-by":"publisher","first-page":"e14328","DOI":"10.1371\/journal.pone.0014328","volume":"5","author":"O Schultz","year":"2010","unstructured":"Schultz O, Oberhauser F, Saech J, Rubbert-Roth A, Hahn M, Krone W, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One. 2010;5(12):e14328. https:\/\/doi.org\/10.1371\/journal.pone.0014328.","journal-title":"PLoS One"},{"issue":"9","key":"867_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024719","volume":"6","author":"HK Berthold","year":"2011","unstructured":"Berthold HK, Laudes M, Krone W, Gouni-Berthold I. Association between the interleukin-6 promoter polymorphism -174G\/C and serum lipoprotein(a) concentrations in humans. PLoS One. 2011;6(9):e24719. https:\/\/doi.org\/10.1371\/journal.pone.0024719.","journal-title":"PLoS One"},{"issue":"1","key":"867_CR57","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13075-020-02163-6","volume":"22","author":"C Gabay","year":"2020","unstructured":"Gabay C, Burmester GR, Strand V, Msihid J, Zilberstein M, Kimura T, et al. Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes. Arthritis Res Ther. 2020;22(1):70. https:\/\/doi.org\/10.1186\/s13075-020-02163-6.","journal-title":"Arthritis Res Ther"},{"issue":"13","key":"867_CR58","doi-asserted-by":"publisher","first-page":"382","DOI":"10.15585\/mmwr.mm6913e2","volume":"69","author":"Team CC-R","year":"2020","unstructured":"Team CC-R. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 - United States, February 12\u2013March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382\u20136. https:\/\/doi.org\/10.15585\/mmwr.mm6913e2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"867_CR59","first-page":"1","volume":"142","author":"AP Bartel","year":"2019","unstructured":"Bartel AP, Kim S, Nam J. Racial and ethnic disparities in access to and use of paid family and medical leave: evidence from four nationally representative datasets. Monthly Lab Rev. 2019;142:1.","journal-title":"Monthly Lab Rev"},{"key":"867_CR60","doi-asserted-by":"publisher","unstructured":"Ferdinand KC, Nasser SA. African American COVID-19 mortality: a sentinel event. J Am Coll Cardiol. 2020. https:\/\/doi.org\/10.1016\/j.jacc.2020.04.040An overview of increase morbidity and mortality due to COVID-19 found in the African American population.","DOI":"10.1016\/j.jacc.2020.04.040"},{"issue":"2","key":"867_CR61","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","volume":"71","author":"S Tsimikas","year":"2018","unstructured":"Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, et al. NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol. 2018;71(2):177\u201392. https:\/\/doi.org\/10.1016\/j.jacc.2017.11.014.","journal-title":"J Am Coll Cardiol"},{"key":"867_CR62","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.brainresbull.2017.04.017","volume":"132","author":"YY Fan","year":"2017","unstructured":"Fan YY, Cai QL, Gao ZY, Lin X, Huang Q, Tang W, et al. APOE epsilon4 allele elevates the expressions of inflammatory factors and promotes Alzheimer\u2019s disease progression: a comparative study based on Han and She populations in the Wenzhou area. Brain Res Bull. 2017;132:39\u201343. https:\/\/doi.org\/10.1016\/j.brainresbull.2017.04.017.","journal-title":"Brain Res Bull"},{"issue":"5","key":"867_CR63","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12170-010-0118-4","volume":"4","author":"MN Haan","year":"2010","unstructured":"Haan MN, Mayeda ER. Apolipoprotein E genotype and cardiovascular diseases in the elderly. Curr Cardiovasc Risk Rep. 2010;4(5):361\u20138. https:\/\/doi.org\/10.1007\/s12170-010-0118-4.","journal-title":"Curr Cardiovasc Risk Rep"},{"issue":"9","key":"867_CR64","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/oxfordjournals.aje.a009711","volume":"148","author":"BV Howard","year":"1998","unstructured":"Howard BV, Gidding SS, Liu K. Association of apolipoprotein E phenotype with plasma lipoproteins in African-American and white young adults. The CARDIA Study. Coronary Artery Risk Development in Young Adults. Am J Epidemiol. 1998;148(9):859\u201368. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a009711.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"867_CR65","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1046\/j.1469-1809.1999.6340301.x","volume":"63","author":"RM Corbo","year":"1999","unstructured":"Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE* 4 a \u2018thrifty\u2019allele? Ann Hum Genet. 1999;63(4):301\u201310.","journal-title":"Ann Hum Genet"},{"key":"867_CR66","doi-asserted-by":"publisher","unstructured":"Goldstein MR, Poland GA, Graeber CW. Does apolipoprotein E genotype predict COVID-19 severity?. QJM: monthly journal of the Association of Physicians, hcaa142. Advance online publication. 2020. https:\/\/doi.org\/10.1093\/qjmed\/hcaa142. A concise review of the potential association of ApoE4 isoforms to COVID-19 response and possible explanation for racial disparity.","DOI":"10.1093\/qjmed\/hcaa142"},{"issue":"9","key":"867_CR67","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1161\/atvbaha.118.312261","volume":"39","author":"C Rieker","year":"2019","unstructured":"Rieker C, Migliavacca E, Vaucher A, Baud G, Marquis J, Charpagne A, et al. Apolipoprotein E4 expression causes gain of toxic function in isogenic human induced pluripotent stem cell-derived endothelial cells. Arterioscler Thromb Vasc Biol. 2019;39(9):e195\u2013207. https:\/\/doi.org\/10.1161\/atvbaha.118.312261.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"867_CR68","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1161\/atvbaha.116.308704","volume":"37","author":"PM Moriarty","year":"2017","unstructured":"Moriarty PM, Varvel SA, Gordts PL, McConnell JP, Tsimikas S. Lipoprotein(a) mass levels increase significantly according to APOE genotype: an analysis of 431 239 patients. Arterioscler Thromb Vasc Biol. 2017;37(3):580\u20138. https:\/\/doi.org\/10.1161\/atvbaha.116.308704An analysis of greater than 400,000 patients demonstrating the association of lipoprotein(a) mass levels to apoE genotype.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"867_CR69","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","volume":"36","author":"S Varvel","year":"2016","unstructured":"Varvel S, McConnell JP, Tsimikas S. Prevalence of elevated Lp (a) mass levels and patient thresholds in 532 359 patients in the United States. Arterioscler Thromb Vasc Biol. 2016;36(11):2239\u201345.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"19","key":"867_CR70","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.jacc.2014.01.055","volume":"63","author":"A Ravandi","year":"2014","unstructured":"Ravandi A, Leibundgut G, Hung MY, Patel M, Hutchins PM, Murphy RC, et al. Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans. J Am Coll Cardiol. 2014;63(19):1961\u201371. https:\/\/doi.org\/10.1016\/j.jacc.2014.01.055.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"867_CR71","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.jacl.2019.09.010","volume":"13","author":"PM Moriarty","year":"2019","unstructured":"Moriarty PM, Gray JV, Gorby LK. Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease. J Clin Lipidol. 2019;13(6):894\u2013900. https:\/\/doi.org\/10.1016\/j.jacl.2019.09.010.","journal-title":"J Clin Lipidol"},{"key":"867_CR72","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.atherosclerosissup.2017.05.028","volume":"30","author":"C Stefanutti","year":"2017","unstructured":"Stefanutti C, Mazza F, Pasqualetti D, Di Giacomo S, Watts GF, Massari MS, et al. Lipoprotein apheresis downregulates IL-1alpha, IL-6 and TNF-alpha mRNA expression in severe dyslipidaemia. Atheroscler Suppl. 2017;30:200\u20138. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2017.05.028.","journal-title":"Atheroscler Suppl"},{"issue":"20","key":"867_CR73","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1093\/eurheartj\/ehx178","volume":"38","author":"TZ Khan","year":"2017","unstructured":"Khan TZ, Hsu L-Y, Arai AE, Rhodes S, Pottle A, Wage R, et al. Apheresis as novel treatment for refractory angina with raised lipoprotein (a): a randomized controlled cross-over trial. Eur Heart J. 2017;38(20):1561\u20139.","journal-title":"Eur Heart J"},{"issue":"3","key":"867_CR74","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1905239A phase 2 trial demonstrating the 80% reduction of lipoprotein(a) with an antisense apolipoprotein(a) pharmacotherapy.","journal-title":"N Engl J Med"},{"issue":"suppl_1","key":"867_CR75","first-page":"A17167","volume":"134","author":"S Melquist","year":"2016","unstructured":"Melquist S, Wakefield D, Hamilton H, Chapman C, Grondolsky J, Schienebeck C, et al. Targeting apolipoprotein (a) with a novel RNAi delivery platform as a prophylactic treatment to reduce risk of cardiovascular events in individuals with elevated lipoprotein (a). Circulation. 2016;134(suppl_1):A17167\u2013A.","journal-title":"Circulation"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-020-00867-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-020-00867-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-020-00867-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T11:53:59Z","timestamp":1667562839000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-020-00867-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,25]]},"references-count":75,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["867"],"URL":"https:\/\/doi.org\/10.1007\/s11883-020-00867-3","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,25]]},"assertion":[{"value":"25 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Erik Stroes reports personal fees from Amgen, Akcea, Sanofi-Regeneron, Esperion, and Novartis outside the submitted work. John Kastelein reports personal fees from AstraZeneca, CIVI Biotechnology, CSL Behring, Draupnir, Esperion, Gemphire, Madrigal Pharmaceuticals, Matinas BioPharma, NorthSea Therapeutics, Novo Nordisk, Novartis, Regeneron, RegenXBio, Staten Biotech, 89Bio, Omeicos, and Serometrix outside the submitted work. Michael Davidson reports he is the Chief Medical Officer of Corvidia Therapeutics. Sotirios Tsimikas reports personal fees from Ionis Pharmaceuticals, being co-founder of Oxitope, Inc., and Kleanthi Diagnostics, LLC, outside the submitted work. In addition, Dr. Tsimikas has a patent for methods of identifying a subject having or at risk of having or developing coronary artery disease with royalties paid to Kleanthi Diagnostics; two patents for methods for assessing atherogenesis by determining oxidized phospholipid to apolipoprotein B ratios with royalties paid to Kleanthi Diagnostics; and a patent for oxidative biomarkers in predicting risk of stroke, transient ischemic attack (TIA), and peripheral arterial disease (PAD) with royalties paid to Kleanthi Diagnostics. Patrick M. Moriarty and Lauryn K. Gorby declare no conflicts of interest relevant to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"48"}}